Follow-up and gene groupings of SAA patients by IBMFS-associated variant status categories
| Variable . | No variant (n = 611) . | Carrier (n = 73) . | Unrecognized IBMFS (n = 48) . | P . |
|---|---|---|---|---|
| Alive at last follow-up, n (%)* | 403 (66) | 51 (70) | 22 (46) | .01† |
| Follow-up of survivors (mo), median (range) | 71 (2-295) | 58 (7-295) | 49 (9-125) | .06‡ |
| Gene group, n (%) | <.001§ | |||
| DNA damage response | 0 (0) | 42 (58) | 6 (13) | |
| Hematopoiesis | 0 (0) | 11 (15) | 21 (44) | |
| Ribosome biology | 0 (0) | 9 (12) | 6 (13) | |
| Telomere biology | 0 (0) | 11 (15) | 15 (31) | |
| No variant | 611 (100) | 0 (0) | 0 (0) |
| Variable . | No variant (n = 611) . | Carrier (n = 73) . | Unrecognized IBMFS (n = 48) . | P . |
|---|---|---|---|---|
| Alive at last follow-up, n (%)* | 403 (66) | 51 (70) | 22 (46) | .01† |
| Follow-up of survivors (mo), median (range) | 71 (2-295) | 58 (7-295) | 49 (9-125) | .06‡ |
| Gene group, n (%) | <.001§ | |||
| DNA damage response | 0 (0) | 42 (58) | 6 (13) | |
| Hematopoiesis | 0 (0) | 11 (15) | 21 (44) | |
| Ribosome biology | 0 (0) | 9 (12) | 6 (13) | |
| Telomere biology | 0 (0) | 11 (15) | 15 (31) | |
| No variant | 611 (100) | 0 (0) | 0 (0) |